Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.67B
Market cap1.67B
Price-Earnings ratio
-3.94
Price-Earnings ratio-3.94
Dividend yield
Dividend yield
Average volume
1.73M
Average volume1.73M
High today
$28.46
High today$28.46
Low today
$26.72
Low today$26.72
Open price
$28.07
Open price$28.07
Volume
145.58K
Volume145.58K
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

The current Agios(AGIO) stock price is $28.06, with a market capitalization of 1.67B. The stock trades at a price-to-earnings (P/E) ratio of -3.94.

During the trading session on 2026-04-30, Agios(AGIO) shares reached a daily high of $28.46 and a low of $26.72. At a current price of $28.06, the stock is +5.0% higher than the low and still -1.4% under the high.

Trading activity shows a volume of 145.58K, compared to an average daily volume of 1.73M.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

AGIO News

TipRanks 2h
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist

Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $39 and keeps a Buy rating on the shares. The company’s Q1 earnings included...

Nasdaq 16h
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday

Key Points It brought in nearly $21 million in the first quarter. Mitapivat has been approved by the FDA for the treatment of two blood disorders. 10 stocks...

Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Simply Wall St 6d
Do Agios Pharmaceuticals’ EPS Revisions Hint At A Turning Point In Its Investment Story?

Agios Pharmaceuticals recently prepared to report its March 2026 quarter results, with analysts expecting a loss but anticipating higher year-over-year revenue...

Do Agios Pharmaceuticals’ EPS Revisions Hint At A Turning Point In Its Investment Story?

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

More AGIO News

Nasdaq 6d
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)

Key Points Agios' price target was lowered due to increased regulatory risk. Novo Nordisk's etavopivat outperformed Agios' mitapivat in Phase 3 trials. Agios...

Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.